Molecular Templates, Inc. (Nasdaq: MTEM), a biopharmaceutical company, received positive news from the U.S. Food and Drug Administration (FDA) regarding its MT-0169 trial. 
The FDA has lifted the partial clinical hold on patient enrollment, allowing Molecular Templates to proceed with the evaluation of the efficacy of MT-0169, an engineered toxin body (ETB) that targets CD38 in Multiple Myeloma.

$MTEM experienced a pre-market surge, trading at $0.51 with a gain of $0.04 (+8.51%), following the announcement.

Duluth Holdings Inc. (Nasdaq: DLTH), a retailer specializing in workwear and accessories, reported a loss of $0.12 per share in the first quarter of 2023, slightly better than the consensus estimate of a loss of $0.13 per share.

In pre-market, $DLTH was trading at $5.50, up $0.10 (+1.85%).

Caleres, Inc. (NYSE: CAL), a footwear company, reported first-quarter 2023 earnings per share (EPS) of $0.97, surpassing the consensus estimate of $0.93. 

Despite facing challenges in the operating environment at Famous Footwear, the company achieved a solid financial performance, driven by record quarterly profit from the Brand Portfolio.

$CAL was trading at $17.00 in pre-market, experiencing a decrease of $0.26 (-1.51%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)